Citi analyst Geoff Meacham lowered the firm’s price target on Pfizer (PFE) to $29 from $30 and keeps a Neutral rating on the shares. Ahead of the Q4 earnings, the firm updated models for its biotechnology and pharmaceuticals coverage. Higher-growth names like Eli Lilly (LLY) and Vertex VRTX) remain Citi’s favorites in the group, given their “strong demand” in key franchises and a lower impact from potential policy changes. The sector “looks tricky” in 2025 given negative sentiment, but growth expectations appear beatable with a focus on commercial execution, the analyst tells investors in a research note.
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PFE:
- Drugmakers modestly raise price on drugs at start of year, WSJ reports
- Starboard did not nominate Pfizer board members, Bloomberg says
- Pfizer (PFE) Pays $59.7 Million Fine to Resolve Charges in Kickback Scheme
- Pfizer to pay ~$60M to settle Medicare false claims
- Viking Therapeutics (VKTX) Stock Could Rise 200%, Says Jefferies